We are very pleased to announce that Elekta recently acquired a minority stake in iRT Systems GmbH to improve its quality assurance offering to clinics and hospitals around the world.
IQM is the first independent verification system available on the market that verifies the treatment accuracy in real-time during the treatment fraction. IQM is completely integrated into the treatment planning and delivery process as a fully automated background process. The innovative IQM detector design combines unrivaled precision with unmatched reproducibility for all modern treatment techniques, including SRT/SBRT, VMAT, large-field IMRT, and TBI, as well as gated treatment delivery and hypo-fractionated treatments.
Click here for more information about the unrivaled verification accuracy of IQM.
“Elekta relentlessly pursues the advancement of treatment quality assurance – through innovation, collaboration or procurement – by elevating quality control at all stages of the workflow” said Maurits Wolleswinkel, Head of Portfolio and Chief Strategy Officer at Elekta. “With our stake in iRT, we can help ensure that all oncology departments can do so, more accurately, efficiently and reliably, by using IQM.”
Jürgen Oellig, Managing Director at iRT, said: “By investing in IQM, clinics are investing in the most advanced quality assurance technology, uniquely offering real-time verification during the patient treatment. And by investing in iRT, Elekta will be providing a solution which will allow its customers to automate all their dosimetric QA processes so they can provide the best possible treatment quality and a new level of safety for their patients.”
IQM has CE mark and FDA 510(k) clearance as well as regulatory approvals in Canada, Australia and many other countries.